Castle Biosciences (NASDAQ:CSTL) PT Lowered to $44.00

Castle Biosciences (NASDAQ:CSTLGet Rating) had its price objective reduced by equities researchers at Robert W. Baird from $50.00 to $44.00 in a research report issued on Tuesday, The Fly reports. Robert W. Baird’s price target would indicate a potential upside of 129.53% from the company’s previous close.

A number of other research analysts have also recently weighed in on CSTL. Zacks Investment Research cut shares of Castle Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, April 28th. Lake Street Capital cut their price objective on shares of Castle Biosciences from $94.00 to $63.00 in a report on Tuesday, March 1st. Canaccord Genuity Group dropped their target price on shares of Castle Biosciences from $94.00 to $80.00 and set a “buy” rating on the stock in a research report on Tuesday, April 5th. Finally, Canaccord Genuity Group dropped their target price on shares of Castle Biosciences from $94.00 to $80.00 and set a “buy” rating on the stock in a research report on Tuesday, April 5th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Castle Biosciences presently has a consensus rating of “Buy” and a consensus price target of $64.71.

CSTL opened at $19.17 on Tuesday. Castle Biosciences has a fifty-two week low of $19.00 and a fifty-two week high of $78.92. The firm has a fifty day moving average price of $34.62. The stock has a market capitalization of $488.57 million, a PE ratio of -15.46 and a beta of 1.11.

Castle Biosciences (NASDAQ:CSTLGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.30). Castle Biosciences had a negative net margin of 33.26% and a negative return on equity of 7.49%. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. As a group, analysts predict that Castle Biosciences will post -2.56 EPS for the current year.

In related news, Director Daniel Bradbury sold 8,852 shares of the business’s stock in a transaction dated Wednesday, February 9th. The shares were sold at an average price of $46.53, for a total transaction of $411,883.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 35,408 shares of company stock worth $1,496,696. Company insiders own 15.40% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ensign Peak Advisors Inc acquired a new position in Castle Biosciences during the fourth quarter worth about $38,000. First Horizon Advisors Inc. boosted its position in Castle Biosciences by 161.5% during the third quarter. First Horizon Advisors Inc. now owns 999 shares of the company’s stock worth $57,000 after acquiring an additional 617 shares during the last quarter. UBS Group AG boosted its position in Castle Biosciences by 84.7% during the third quarter. UBS Group AG now owns 1,256 shares of the company’s stock worth $83,000 after acquiring an additional 576 shares during the last quarter. Moors & Cabot Inc. acquired a new position in Castle Biosciences during the third quarter worth about $113,000. Finally, Royal Bank of Canada boosted its position in Castle Biosciences by 15.3% during the second quarter. Royal Bank of Canada now owns 1,775 shares of the company’s stock worth $130,000 after acquiring an additional 235 shares during the last quarter. Hedge funds and other institutional investors own 84.29% of the company’s stock.

Castle Biosciences Company Profile (Get Rating)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

See Also

The Fly logo

Analyst Recommendations for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.